Related references
Note: Only part of the references are listed.Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases
Arezoo Hosseini et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
2′-fucosyllactose inhibits imiquimod-induced psoriasis in mice by regulating Th17 cell response via the STAT3 signaling pathway
Ke Lei et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Epigenetic mechanisms shape the underlining expression regulatory mechanisms of the STAT3 in multiple sclerosis disease
Arezoo Hosseini et al.
BMC RESEARCH NOTES (2020)
The Dichotomous Nature of AZ5104 (an EGFR Inhibitor) Towards RORγ and RORγT
Kaja Karas et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis
Arezoo Hosseini et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation
Katja G. Weinacht et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Diagnosis of multiple sclerosis: progress and challenges
Wallace J. Brownlee et al.
LANCET (2017)
Janus kinase inhibitors for rheumatoid arthritis
Kunihiro Yamaoka
CURRENT OPINION IN CHEMICAL BIOLOGY (2016)
JAK1/2 inhibition impairs T cell function invitro and in patients with myeloproliferative neoplasms
Sowmya Parampalli Yajnanarayana et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells
Clodagh Keohane et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Ruxolitinib Attenuates Cutaneous Lupus Development in a Mouse Lupus Model
Emilie S. Chan et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Therapeutic Efficacy of Suppressing the JAK/STAT Pathway in Multiple Models of Experimental Autoimmune Encephalomyelitis
Yudong Liu et al.
JOURNAL OF IMMUNOLOGY (2014)
JAK2-STAT3 Blockade by AG490 Suppresses Autoimmune Arthritis in Mice via Reciprocal Regulation of Regulatory T Cells and Th17 Cells
Jin-Sil Park et al.
JOURNAL OF IMMUNOLOGY (2014)
Involvement of the Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathway in Multiple Sclerosis and the Animal Model of Experimental Autoimmune Encephalomyelitis
Etty N. Benveniste et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2014)
Janus kinase inhibitors in autoimmune diseases
John J. O'Shea et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Therapeutic Blockade of Interleukin-6 in Chronic Inflammatory Disease
K. Yamamoto et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity1
Timothy J. Harris et al.
JOURNAL OF IMMUNOLOGY (2007)
STAT3 regulates cytokine-mediated generation of inflammatory helper T cells
Xuexian O. Yang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells
Ivaylo I. Ivanov et al.
CELL (2006)
A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis
Caroline Sutton et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
E Bettelli et al.
NATURE (2006)
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
PC Heinrich et al.
BIOCHEMICAL JOURNAL (2003)
Pathogenesis of multiple sclerosis: an update on immunology
B Hemmer et al.
CURRENT OPINION IN NEUROLOGY (2002)
Share Paper
